Biomarker study of Atezolizumab plus Bevacizumab for PD-L1 High Non-Sq NSCLC

Biomarker study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression Non-Small Cell Non-Squamous Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224072

Enrollment

Registered

2018-10-01

Start date

2019-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell lung cancer

Interventions

investigational material(s) Generic name etc : Atezolizumab with bevacizumab are administrated in WJOG10718L (A Phase II Study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient enrolled into WJOG10718L (A Phase II Study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression Non-Small Cell Non-Squamous Cell Lung Cancer) 2. Written informed consent to biomarker study

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy The correlation between immunological biomarker and the efficacy and safety in WJOG10718L Retrospective analysis to explore the immunological biomarkers (bTMB /LC-SCRUM-IBIS /LC-SCRUM-Liquid) related to the efficacy and safety in WJOG10718L will be performed	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026